Workflow
Neumora Therapeutics(NMRA)
icon
搜索文档
NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
Prnewswire· 2025-04-06 06:20
文章核心观点 - 法律事务所Kessler Topaz Meltzer & Check, LLP告知投资者,已代表在Neumora Therapeutics首次公开募股前后购买其普通股的投资者对该公司提起证券集体诉讼,指控被告在招股文件中存在重大虚假或误导性陈述,未披露关键信息,首席原告申请截止日期为2025年4月7日 [1][3][4] 诉讼相关信息 - 诉讼针对Neumora Therapeutics,代表在其2023年9月15日左右首次公开募股中依据招股文件购买普通股的投资者 [1] - 首席原告申请截止日期为2025年4月7日,投资者可通过Kessler Topaz Meltzer & Check, LLP或其他律师申请成为首席原告代表集体诉讼,也可选择不作为保持缺席集体成员身份,是否担任首席原告不影响赔偿分享 [1][4] 被告被指控不当行为 - 被告在招股文件中存在重大虚假或误导性陈述,未披露为开展三期项目,Neumora修改二期试验纳入标准,将中重度重度抑郁症患者纳入以显示Navacaprant治疗效果有统计学显著改善 [3] - 被告未披露Neumora在二期统计分析计划中增加针对中重度重度抑郁症患者的预设分析 [3] - 被告未披露二期试验缺乏足够数据,特别是患者群体规模和男女患者比例数据,无法准确预测KOASTAL - 1研究结果 [3] 律所相关信息 - Kessler Topaz Meltzer & Check, LLP鼓励遭受重大损失的Neumora投资者联系获取更多信息,可点击链接或联系律师Jonathan Naji [2][5] - 该律所擅长在国内外州和联邦法院提起集体诉讼,为欺诈和企业不当行为受害者追回数十亿美元,目标是保护投资者等免受欺诈等行为侵害,此诉讼投诉非该律所提交 [5] 联系方式 - 联系Kessler Topaz Meltzer & Check, LLP可点击链接https://www.ktmc.com/new - cases/neumora - therapeutics - inc?utm_source=PR&utm_medium=link&utm_campaign=nma&mktm=r,或联系律师Jonathan Naji,电话(484) 270 - 1453,邮箱[email protected] [2][6]
NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm
Prnewswire· 2025-04-05 04:05
NEW YORK, April 4, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm.So what: If you purchas ...
NMRA Investors Have Opportunity to Lead Neumora Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Prnewswire· 2025-04-04 07:10
文章核心观点 Faruqi & Faruqi律所正调查针对Neumora Therapeutics的潜在索赔,提醒投资者2025年4月7日截止申请担任联邦证券集体诉讼的首席原告,鼓励在Neumora损失超5万美元的投资者联系讨论法律权利,也鼓励知情者提供信息 [1][2] 律所信息 - Faruqi & Faruqi是领先的国家证券律师事务所,在纽约、宾夕法尼亚、加利福尼亚和佐治亚设有办事处,自1995年成立以来已为投资者追回数亿美元 [3] 公司情况 - Neumora Therapeutics在2023年9月进行首次公开募股 [1] - 2025年1月2日,Neumora宣布其实验性抑郁症治疗药物在三项研究的第一项中失败,navacaprant在III期Koastal - 1试验中治疗抑郁症症状与安慰剂无差异,消息公布后NMRA股价暴跌81%,收于每股1.97美元 [5] 诉讼相关 - 投诉称公司及其高管违反联邦证券法,包括修改试验纳入标准、增加预设分析、二期试验数据不足等,导致投资者受损 [4] - 法院指定的首席原告是在集体寻求的救济中拥有最大经济利益、能代表集体成员指导和监督诉讼的投资者,集体成员可申请担任或不作为缺席成员,是否担任不影响赔偿分享 [6] 联系方式 - 投资者可拨打Faruqi & Faruqi合伙人Josh Wilson电话877 - 247 - 4292或212 - 983 - 9330(分机1310)讨论法律权利,也可访问www.faruqilaw.com/NMRA了解集体诉讼详情 [1][8] - Faruqi & Faruqi鼓励知情者联系该律所 [7]
NMRA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
GlobeNewswire News Room· 2025-04-04 02:12
文章核心观点 Rosen Law Firm提醒Neumora Therapeutics股票购买者证券集体诉讼首席原告截止日期,购买者或可获赔偿并告知加入诉讼方式,还介绍律所优势及案件详情 [1][2][3] 分组1:提醒信息 - Rosen Law Firm提醒Neumora Therapeutics普通股购买者2025年4月7日是证券集体诉讼首席原告截止日期 [1] 分组2:赔偿权益 - 购买Neumora普通股者或可通过风险代理安排获赔偿且无需支付额外费用 [2] 分组3:参与方式 - 可访问https://rosenlegal.com/submit - form/?case_id = 34655 或致电866 - 767 - 3653或发邮件至case@rosenlegal.com加入集体诉讼,若想担任首席原告须在2025年4月7日前向法院申请 [3][6] 分组4:律所优势 - Rosen Law Firm代表全球投资者,专注证券集体诉讼和股东派生诉讼,曾达成针对中国公司最大证券集体诉讼和解,2017年证券集体诉讼和解数量排名第一,2013年以来每年排名前4,为投资者追回数亿美元,2019年为投资者获超4.38亿美元赔偿,2020年创始合伙人获荣誉,多位律师获认可 [4] 分组5:案件详情 - 诉讼称招股文件含虚假或误导性陈述,未披露为开展三期项目修改二期试验纳入标准、增加预设分析及二期试验数据不足等情况,真相公开后投资者受损 [5]
Shareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA
Prnewswire· 2025-04-03 17:45
NEW YORK, April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=140382&from=4 CLASS PERIOD: ...
NMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit
GlobeNewswire News Room· 2025-04-03 05:30
文章核心观点 Kessler Topaz Meltzer & Check, LLP告知投资者已对Neumora Therapeutics, Inc.提起证券集体诉讼,指控其在招股文件中存在重大虚假或误导性陈述,Neumora投资者可在4月7日2025前申请成为首席原告 [1][2][3] 诉讼相关信息 - 诉讼已在美国纽约南区地方法院对Neumora Therapeutics, Inc.提起,代表在2023年9月15日左右首次公开募股中购买该公司普通股的投资者 [1] - 首席原告申请截止日期为2025年4月7日 [1][3] 被告涉嫌不当行为 - 被告在招股文件中作出重大虚假或误导性陈述,未披露为开展三期项目,Neumora修改二期试验纳入标准以显示Navacaprant治疗重度抑郁症有显著改善 [2] - 被告未披露Neumora在二期统计分析计划中增加针对中重度抑郁症患者的预设分析 [2] - 被告未披露二期试验缺乏足够数据,无法准确预测KOASTAL - 1研究结果 [2] 首席原告流程 - Neumora投资者可在2025年4月7日前通过Kessler Topaz Meltzer & Check, LLP或其他律师申请成为首席原告代表集体诉讼,也可选择不作为缺席集体成员 [3] - 首席原告通常是财务利益最大且能代表投资者群体的投资者或小团体,其选择的律师需经法院批准 [3] - 是否担任首席原告不影响投资者分享赔偿的权利 [3] 律所信息 - Kessler Topaz Meltzer & Check, LLP在国内外各级法院提起集体诉讼,为欺诈和企业不当行为受害者追回数十亿美元 [4] - 该律所目标是保护投资者、消费者、员工等免受企业和信托机构欺诈、滥用、不当行为和疏忽的侵害 [4] 联系方式 - 遭受损失的投资者可点击链接或联系律师Jonathan Naji获取更多信息,电话(484) 270 - 1453,邮箱info@ktmc.com [2][4] - 律所地址为280 King of Prussia Road, Radnor, PA 19087 [5][6]
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
GlobeNewswire News Room· 2025-04-02 01:42
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/ ...
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 7, 2025 Deadline to file Lead Plaintiff Motion
GlobeNewswire News Room· 2025-04-01 05:02
Please visit our website to review more information and submit your transaction information. Investors can contact the law firm at no cost to learn more about recovering their losses The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm adv ...
Shareholders that lost money on Neumora Therapeutics, Inc. (NMRA) should contact The Gross Law Firm about pending Class Action - NMRA
GlobeNewswire News Room· 2025-04-01 01:12
https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=139438&from=3 CLASS PERIOD: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023. NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purch ...
NMRA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA
GlobeNewswire News Room· 2025-04-01 01:01
NMRA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") is ...